Any updates from the people using maraviroc? Benefits, side effects, and dosing you’re using?
1 Like
not much to report other than my grip strength went from 38 to 42. If I don’t take it for couple weeks or so the grip strength seems to taper off and get back to the base line of about 38. No other benefits or side effects. At some point I thought it made me a bit agitated, but I’m not 100% sure of it. Nothing else good or bad. I had bought 3 bottles and intend to finish them and take a break for a while if I feel different and then I’ll make my decision if I want to do it longer term. I do 1/2 a pill twice a day.
3 Likes
I have been taking 75 mg of maraviroc daily for approximately 4 weeks. I split the 150 mg tablet in half and take it in the morning. ZERO subjective effects or noticeable effects on any routine blood markers, though I had only been taking maraviroc for about 2 weeks before my latest blood test.
Hoping my natural skepticism is not affecting the outcome.
My advice (certainly not medical) is to wait a while for more human studies, or at least for anecdotal results from forum members, before spending your money on maraviroc.
Starting tomorrow, I will take 150 mg in the morning, at least 1 hour before breakfast.
After 90 days, if I don’t find any subjective improvements, I will stop wasting my money on it, as the cost-benefit ratio won’t be attractive to me. The only blood markers I routinely take that I might see improvement in are inflammation markers like hsCRP.
From Claude Opus 4.7:
What 75 mg daily actually represents pharmacologically
The case for 75 mg QD being plausibly active:
- Receptor occupancy is high even at low doses. CCR5 occupancy is the pharmacodynamic driver for maraviroc’s effects, and it saturates well below the 300 mg BID HIV dose. Modeling suggests 75 mg once daily produces peak CCR5 occupancy around 96–98% and average occupancy around 82–89%, with trough occupancy dropping to ~44%. For a senomorphic effect (damping chronic SASP signaling), you may not need 24-hour full occupancy — intermittent blockade may be sufficient to suppress sustained CCL3/4/5 → CCR5 tonic signaling.
- The mechanism is inflammation/SASP suppression, not acute viral entry inhibition. Unlike HIV, where any unblocked receptor means potential viral entry, a senomorphic effect is about dampening chronic inflammatory tone. That’s more forgiving of partial/intermittent blockade.
- Dose-response in HIV is flat above ~75–150 mg. The 300 mg BID dose was chosen with viral safety margins, not because lower doses were ineffective at CCR5 engagement.
The case against 75 mg QD being sufficient:
- Zero human efficacy data for sarcopenia at any dose. The CUHK study is in 18-month-old mice at 10 mg/kg IP — which, even correcting for the 1400-fold lower affinity at mouse CCR5, represents a very different receptor-engagement scenario than oral human dosing.
- Muscle tissue penetration is not well-characterized. Maraviroc is ~76% protein-bound and concentrates in some tissues (lymphoid, gut) more than others. How much reaches the skeletal muscle stem cell niche at 75 mg QD is unknown.
- The CUHK mouse benefit came from high exposure. The “high-dose short-term” arm (10 mg/kg IP × 3 months) is what produced the muscle phenotype. Lower-dose arms exist but the full dose-response in aged mice has not been published in a form that lets you extrapolate a minimum effective human dose.
- Age, sex, baseline inflammation, and muscle-use history likely matter more than dose. In the CUHK paper, the drug only helped aged mice. If you don’t have a substantial senescent-cell burden in your muscle to begin with, there may be nothing for maraviroc to suppress regardless of dose.
75 mg daily is in the range where some biological effect on CCR5 signaling is plausible, but whether that translates into meaningful muscle preservation in a specific human is genuinely unknown — and would likely be small-to-undetectable over months, possibly meaningful over years, possibly nothing. The CUHK result is one mouse study. It has not been replicated, has not been tested in humans, and the mechanism (senomorphic SASP suppression) would predict gradual rather than dramatic effects.
7 Likes